Oncoproteins are produced from oncogenic gene expression as result of mutation of a normal gene into an onco gene, one which may have the potential to cause cancer.
Proto oncogenes are normal ones which carry the potential to be cancer forming ones, and can be triggered through mutagenic processes, cell growth misregulation or an abnormal translocation of a chromosome
New research indicates that antibodies can target intracelluar oncoproteins. Most recently it was thought that oncoproteins like PRL-3 could not be accessed via antibody attack as antibodies were too big to relocate them selves into the cell via the cell membrane.
|
|
Fibronectin Antibody - Mouse Anti-Human Fibronectin
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape.Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling
£226.00
MERTK Antibody- Mouse Anti-Mer Receptor Tyrosine Kinase
In vertebrates the photoreceptor cells are the basic sensory apparatus of the retina primarily converting photon energy absorbed from light into neuronal signals The photoreceptor proximal outer segments are synthesized daily by cell bodies and outer segment tips are removed with a circadian rhythm The shed outer segments are endocytosed by adjacent retinal pigment epithelial (RPE) cells and are recycled to photoreceptors The receptor tyrosine kinase MERTK protein is an approximately 120-122 kDa (994 amino acids) protein expressed in RPEs MERTK has a tyrosine kinase domain close to the C-terminal region and putative phosphorylation sites Mutation of MERTK in the Royal College of Surgeons (RCS) rat results in defective phagocytosis of photoreceptor outer segments by the retinal pigment epithelium (RPE) and retinal degeneration resulting in retinitis pigmentosa
£226.00
OVCA1 Antibody- Rabbit Anti-OVCA1
Chromosome 17 is a hotspot for chromosomal aberrations in breast and ovarian cancer. Candidate oncogenes and tumor suppressors located on this chromosome include OVCA1 and OVCA2, p53, BRCA1, HER2/neu and others. OVCA1 and 2 map to a highly conserved region on human chromosome 17p13.3 that is deleted in 80% of ovarian cancers and shows frequent loss of heterozygosity in breast cancers . OVCA1 is induced by BRCA1 and is closely linked to p53, a well-known tumor suppressor gene. The close linkage of OVCA1 and p53 suggests that coordinated loss of the two genes may lead to ovarian, breast and other tumor types
£226.00
OVCA1 Antibody- Rabbit Anti-OVCA1
Chromosome 17 is a hotspot for chromosomal aberrations in breast and ovarian cancer. Candidate oncogenes and tumor suppressors located on this chromosome include OVCA1 and OVCA2, p53, BRCA1, HER2/neu and others. OVCA1 and 2 map to a highly conserved region on human chromosome 17p13.3 that is deleted in 80% of ovarian cancers and shows frequent loss of heterozygosity in breast cancers . OVCA1 is induced by BRCA1 and is closely linked to p53, a well-known tumor suppressor gene. The close linkage of OVCA1 and p53 suggests that coordinated loss of the two genes may lead to ovarian, breast and other tumor types
£183.00
OVCA2 Antibody- Rabbit Anti-OVCA2
Chromosome 17 is a hotspot for chromosomal aberrations in breast and ovarian cancer. Candidate oncogenes and tumor suppressors located on this chromosome include OVCA1 and OVCA2, p53, BRCA1, HER2/neu and others. OVCA1 and 2 map to a highly conserved region on human chromosome 17p13.3 that is deleted in 80% of ovarian cancers and shows frequent loss of heterozygosity in breast cancers . OVCA1 is induced by BRCA1 and is closely linked to p53, a well-known tumor suppressor gene. The close linkage of OVCA1 and p53 suggests that coordinated loss of the two genes may lead to ovarian, breast and other tumor types
£226.00
